The approval is for its ipsogen JAK2 RGQ PCR Kit for additional use in the diagnosis of all MPNs.
QIAGEN Receives FDA Clearance for First-Ever JAK2 Test for Use in Diagnosis of Additional Myeloproliferative Neoplasms |
| [23-January-2018] |
| HILDEN, Germany, and GERMANTOWN, Maryland, January 23, 2018 /PRNewswire/ -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has received clearance for its ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) from the U.S. Food and Drug Administration (FDA) for additional use in the diagnosis of all myeloproliferative neoplasms (MPNs), which are a group of cancers in which immature blood cells in the bone marrow do not mature and become healthy blood cells. Click here [https://corporate.qiagen.com/newsroom/press-releases/2017/20180119_ipsogen_jak2?sc_lang=en ] for the full press release https://corporate.qiagen.com/newsroom/press-releases/2017/20180119_ipsogen_jak2?sc_lang=en Contacts: QIAGEN Investor Relations John Gilardi e-mail: ir@QIAGEN.com +49-2103-29-11711 Public Relations Dr. Thomas Theuringer e-mail: pr@QIAGEN.com +49-2103-29-11826
SOURCE Qiagen N.V. | ||
Company Codes: Frankfurt:QIA, NYSE:QGEN, Bloomberg:QGEN@US, Bloomberg:QIA@GR, RICS:QGEN.F, ISIN:NL0000240000 |
